University of Pittsburgh Medical Center’s venture arm has allocated $1bn to drugs, diagnostics and devices development, including a $200m partnership with the university.

UPMC Enterprises, the investment and innovation arm of healthcare provider University of Pittsburgh Medical Center (UPMC), announced on Tuesday it would invest $1bn in the development of drugs, diagnostics and devices by 2024.
The figure includes a $200m partnership with University of Pittsburgh, announced in early 2018, to establish the Immune Transplant and Therapy Center. That hub will focus on the development of immunotherapies for a wide range of diseases.
UPMC is closely affiliated with University of Pittsburgh’s…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in